DOCSLIB.ORG

Man Kann Ut Mi a Tomutan Untuk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Man Kann Ut Mi a Tomutan Untuk MANKANN UT MIUS009775889B2 A TOMUTAN UNTUK (12 ) United States Patent (10 ) Patent No. : US 9 ,775 , 889 B2 Keller et al. (45 ) Date of Patent: Oct . 3 , 2017 ( 54 ) METHODS OF TREATMENT OF CELLULITE 4 ,645 ,668 A * 2 / 1987 Pinnell .. .. .. 424 / 94 . 2 4 , 769 , 027 A 9 / 1988 Baker et al . .. .. 424 /493 ( 71) Applicant: HALOZYME , INC ., San Diego , CA 4 , 952 ,496 A 8 / 1990 Studier et al . .. .. 435 /91 . 41 (US ) 4 , 983 , 164 A 1 / 1991 Hook et al. .. .. .. .. .. 604 / 139 5 , 033 ,252 A 7 / 1991 Carter . 53 /425 (72 ) Inventors : Gilbert Keller , Belmont, CA (US ) ; 5 ,051 , 449 A 9 / 1991 Kligman .. .. 514 /559 5 , 052 ,558 A 10 / 1991 Carter . .. .. 206 /439 Gregory I . Frost , Palm Beach , FL (US ) 5 , 059 , 595 A 10 /1991 Le Grazie . .. .. .. 424 /468 5 ,073 ,543 A . 514 / 21 (73 ) Assignee : Halozyme, Inc. , San Diego, CA (US ) 5 , 120 ,548 A 6 / 1992 McClelland et al. .. .. .. 424 /473 5 , 122 ,614 A 6 / 1992 Zalipsky .. .. .. .. .. .. 548 / 520 ( * ) Notice : Subject to any disclaimer, the term of this 5 , 171 ,081 A 12 / 1992 Pita et al . .. .. 362 / 101 patent is extended or adjusted under 35 5 , 323 , 907 A 6 / 1994 Kalvelage .. .. .. 206 / 531 U . S . C . 154 ( b ) by 0 days . 5 ,324 , 844 A 6 / 1994 Zalipsky . .. 548 /520 This patent is subject to a terminal dis 5 , 342 ,756 A 8 / 1994 Risteli et al. .. .. 435 / 7 . 21 claimer . 5 ,395 , 326 A 3 / 1995 Haber et al . .. .. .. .. 604 / 191 5 ,446 ,090 A 8 / 1995 Harris . 525 /54 . 1 5 , 523 ,090 A 6 / 1996 Znaiden et al. .. 424 /401 (21 ) Appl. No. : 14 / 243, 805 5 ,536 , 499 A 7 / 1996 Znaiden et al. 424 /401 5 , 538 , 853 A 7 / 1996 Risteli et al. .. .. .. .. 435 / 7 . 9 ( 22 ) Filed : Apr. 2 , 2014 5 ,589 , 171 A 12 / 1996 Wegman .. .. .. 424 / 94 .67 5 ,591 , 767 A 1/ 1997 Mohr et al. 514 / 413 (65 ) Prior Publication Data 5 ,612 ,460 A 3 / 1997 . .. 530 / 391. 9 US 2014 /0271609 A1 Sep . 18 , 2014 5 ,639 ,476 A 6 / 1997 Oshlack et al . .. .. 424 /468 (Continued ) Related U . S . Application Data FOREIGN PATENT DOCUMENTS (63 ) Continuation of application No. 12 / 381, 063, filed on Mar. 6 , 2009 . 0576953 1 / 1994 EP 0822199 9 /2004 ( 60 ) Provisional application No. 61/ 068 , 667, filed on Mar. 6 , 2008 , provisional application No . 61/ 127 ,725 , filed (Continued ) on May 14 , 2008 . OTHER PUBLICATIONS ( 51 ) Int . Ci. Hexel et al , Subcision : a treatment for cellulite . Int J Dermatol . Jul . A61K 38 /48 ( 2006 .01 ) 2000 ; 39 ( 7 ): 539 -44 . * C12N 9 /64 ( 2006 .01 ) Turk et al , Acidic pH as a physiological regulator of human (52 ) U . S . CI. cathepsin L activity . Eur J Biochem . Feb . 1999 ;259 ( 3 ) :926 - 32 . * CPC .. .. .. A61K 38 / 4873 ( 2013 .01 ) ; A61K 38 /482 PIR _ 80 :* database Acc # Khhul from Mason et al, Biochem J . Dec . ( 2013 . 01 ) ; A61K 38 / 488 ( 2013 . 01 ) ; A61K 1 , 1986 ; 240 ( 2 ) : 373 - 7 . Alignment with SEQ ID No : 1 . * 38 /4813 ( 2013 .01 ) ; C12N 9 /6472 ( 2013 .01 ) ; Mason et al , The N - terminal amino acid sequences of the heavy and C12N 9 /6491 (2013 .01 ) ; C12Y 304 / 22015 light chains of human cathepsin L . Biochem J . Dec . 1 , (2013 .01 ) ; C12Y 304 / 24007 (2013 .01 ) 1986 ;240 ( 2 ): 373 - 7 .* (58 ) Field of Classification Search (Continued ) None See application file for complete search history . Primary Examiner — Sheridan Swope ( 56 ) References Cited ( 74 ) Attorney , Agent, or Firm — Dentons US LLP ; U . S . PATENT DOCUMENTS Stephanie Seidman 3 , 536 ,809 A 10 / 1970 Applezweig . .. .. .. .. 424 /28 3 ,539 ,794 A 11/ 1970 Rauhut et al . .. .. .. .. .. 240 / 2 . 25 (57 ) ABSTRACT 3 , 598 , 123 A 8 / 1971 Zaffaroni . .. .. .. .. .. .. 424 / 435 3 ,630 , 200 A 12 / 1971 Higuchi .. 424 / 427 3 , 710 , 795 A 1 / 1973 Higuchi et al . 424 /424 Methods and combinations are provided for controlling the 3 , 845 , 770 A 11/ 1974 Theeuwes et al . .. .. .. .. 424 / 427 duration of action , in vivo , of matrix - degrading enzymes. 3 , 916 , 899 A 11/ 1975 Theeuwes et al. .. .. 424 / 424 The methods and combinations permit temporary in - vivo 4 ,002 , 531 A 1 / 1977 Royer .. .. .. 435 / 188 activation ofmatrix - degrading enzymes upon administration 4 ,008 , 719 A 2 / 1977 Theeuwes et al . .. 424 / 427 4 ,044 , 126 A 8 / 1977 Cook et al. .. 514 / 180 to the extra cellular matrix (or “ ECM ” ) . Matrix -degrading 4 , 179 , 337 A 12 / 1979 Davis et al. .. .. 435 / 181 enzymes having a controlled duration of action can be used 4 , 202 , 314 A 5 / 1980 Smirnov et al . .. .. .. .. .. 128 /218 to treat ECM -mediated diseases or disorders characterized 4 ,214 ,584 A 7 / 1980 Smirnov et al . .. 128 / 218 by increased deposition or accumulation of one or more 4 , 288 ,433 A 9 / 1981 Koulbanis et al . .. 514 / 161 ECM components . 4 ,364 , 923 A 12 / 1982 Cook et al. 424 / 46 4 , 397 , 951 A 8 / 1983 Taki et al . .. .. 435 / 188 4 ,414 , 209 A 11 / 1983 Cook et al. .. .. .. .. .. .. 514 / 180 4 , 529 ,403 A 7 / 1985 Kamstra 604 / 136 23 Claims, 11 Drawing Sheets US 9 , 775 , 889 B2 Page 2 (56 ) References Cited 2003 /0012778 A1 1 /2003 Zimmerman et al. .. .. 424 / 94 .64 2003 / 0026794 A1 * 2 / 2003 Fein . .. .. .. 424 / 94 . 2 U . S . PATENT DOCUMENTS 2003 / 0045495 Al 3 / 2003 Li et al . .. .. 514 /44 R 2003 /0114647 A1 6 / 2003 Harris et al . .. .. .. .. .. 530 / 402 5 ,643 , 575 A 7 / 1997 Martinez et al . 424 / 194 . 1 2003/ 0143596 Al 7 / 2003 Bentley et al . .. .. .. 435 / 6 5 ,667 , 793 A 9 / 1997 Cho et al . 424 / 401 2003/ 0158333 A1 8 / 2003 Roberts et al. .. .. .. .. .. 530 /402 5 ,672 ,662 A 9 / 1997 Harris et al. .. .. .. .. .. .. .. 525 / 408 2003 /0220447 Al 11/ 2003 Harris .. .. .. .. .. 528 /322 5 ,674 ,533 A 10 / 1997 Santus et al . 424 / 493 2004 / 0013637 Al 1 / 2004 Bentley et al. .. 424 /78 . 17 5 ,705 , 170 A 1 / 1998 Kong et al. .. 424 / 401 2004 /0235734 AL 11/ 2004 Bossard . .. 514 / 12 5 , 705 , 364 A 1 / 1998 Etcheverry et al. .. 435 / 70 . 3 2005 / 0042213 Al 2 / 2005 Gelder et al. .. .. .. 424 / 94 .64 5 ,733 , 566 A 3 / 1998 Lewis 424 / 426 2005 / 0114037 Al 5 / 2005 Desjarlais et al. .. .. .. .. .. 702 / 19 5 , 747 ,027 A 5 / 1998 Stern et al. .. 424 / 94 .62 2005 /0171328 Al 8 / 2005 Harris .. .. .. .. ** ** . .. 528520 /322 5 , 747 , 322 A 5 / 1998 Crail et al . .. .. .. .. .. .. .. 435 / 226 2005 / 0209416 Al 9 /2005 Harris . 525 / 523 5 , 766 , 581 A 6 / 1998 Bartley et al . .. .. .. .. .. 424 /85 . 1 2005 /0287134 Al 12 / 2005 Klein . .. .. .. 424 / 94 .61 5 ,788 ,670 A 8 / 191998 Reinnnhard et al. .. .. .. 604 / 191 2007 / 0003541 Al 1 / 2007 Faudoa et al . .. .. .. 424 / 94 .65 5 , 795 , 569 A 8 / 1998 Bartley et al. 424 / 85 . 1 2007 / 0004036 A1 1 / 2007 Faudoa et al . .. .. .. 435 /325 5 . 808 , 096 A 9 / 1998 Zalipsky . .. .. .. .. .. .. .. 548 / 520 2007 /0128685 A1 6 / 2007 Faudoa et al . 435 / 34 5 , 827 , 721 A 10 / 1998 Stern et al. .. .. .. .. 435 / 201 2007 /0224183 A1 9 / 2007 Sabatino et al . .. .. .. .. 424 /94 .67 5 , 830 , 741 A 11/ 1998 Dwulet . .. .. .. .. .. 435 / 220 2007/ 0224184 Al 9 / 2007 Badalemente et al. .. 424 / 94 . 6 5 , 900 , 461 A 5 / 1999 Harris . .. .. .. .. .. .. .. .. 525 / 54 . 11 2008/ 0131500 A1 6 / 2008 Chang . 424 / 451 5 ,919 , 455 A 7 / 1999 Greenwald et al . .. .. 424 / 178 . 1 2009 / 0010918 A1 1 / 2009 Badalemente et al. .. 424 /94 .67 5 , 932 , 462 A 8 / 1999 Harris et al. 435 / 188 2010 /0003237 A1 1 / 2010 Keller et al . .. .. .. 424 / 94 .62 5 , 962 , 482 A 10 / 1999 Bissett 514 / 356 2010 / 0260739 A1 10 / 2010 Short et al. .. .. .. .. .. 424 / 94 . 5 5 , 971, 953 A 10 / 1999 Bachynnnsky .. .. .. .. .. .. 604 / 181 2010 /0284995 AL 11 /2010 Bookbinder et al . .. .. 424 / 94 .62 5 , 976 , 556 A 11/ 1999 Norton et al. .. .. .. .. 424 / 401 2011/ 0152359 Al 6 / 2011 Bookbinder et al. .. .. .. 435 / 200 5 ,985 , 263 A 11/ 1999 Lee et al . .. .. .. 424 / 85 . 2 2012 / 0108455 A1 5 / 2012 Kodandapani et al . .. .. .. 506 / 9 5 , 990 , 237 A 11/ 1999 Bentley et al. .. .. 525 /54 . 2 2012 /0148555 Al 6 /2012 Bookbinder et al. .. .. .. 435 / 200 6 ,022 , 539 A 2 / 2000 Wegman . .. .. .. .. 424 / 94 .67 2012 / 0251620 Al 10 /2012 Bookbinder et al . .. .. .. 424 / 450 6 , 054 , 569 A 4 / 2000 Benett et al. .. .. .. .. .. .. 424 / 945 2013 / 0058893 A1 3 / 2013 Bookbinder et al . .. .. .. 435 /200 6 , 060 ,474 A 5 / 2000 Williams et al . .. .. 514 / 253 .08 2013 /0266579 A1 10 / 2013 Wei et al. .. 424 / 158 . 1 6 ,071 ,526 A 6 / 2000 Schmidt et al . .. .. .. 424 / 401 6 ,086 , 872 A 7 / 2000 Wegman . .. .. .. .. 424 / 94 .67 FOREIGN PATENT DOCUMENTS 6 , 113 , 906 A 9 / 2000 Greenwald et al . .. .. .. 424 / 194 . 1 6 , 153 , 207 A 11/ 2000 Pugliese . .. .. .. .. .. 424 / 402 EP 1064951 8 / 2007 6 , 214 ,966 B1 4 / 2001 Harris 528 / 322 GB 2 323 530 9 / 1998 6 , 258 , 351 B1 . 7 / 2001 Harris . 424 / 78 . 3 JP 6 - 192124 4 / 1994 6 , 274 , 364 B1 8 / 2001 Bernard et al. .. .. 435 / 212 JP 7 - 075573 3 / 1995 6 ,294 ,350 B1 9 / 2001 Peterson .. .. 435 /29 2001 -523943 A 11/ 2001 6 , 340 , 742 B1 1 /2002 Burg et al. .. .. .. .. .. .. .. 530 / 351 MX 331943 7 / 2015 6 , 353 ,028 B2 3 / 2002 Easterling .. .. 514 /654 WO WO 94 / 15848 7 / 1994 6 ,399 , 348 B1 6 /2002 Will et al .
Load more

Recommended publications
  • Supplementary Data
    Supplementary Data for Quantitative Changes in the Mitochondrial Proteome from Subjects with Mild Cognitive Impairment, Early Stage and Late Stage Alzheimer’s disease Table 1 - 112 unique, non-redundant proteins identified and quantified in at least two of the three analytical replicates for all three disease stages. Table 2 - MCI mitochondrial samples, Protein Summary Table 3 - MCI mitochondrial samples, Experiment 1 Table 4 - MCI mitochondrial samples, Experiment 2 Table 5 - MCI mitochondrial samples, Experiment 3 Table 6 - EAD Mitochondrial Study, Protein Summary Table 7 - EAD Mitochondrial Study, Experiment 1 Table 8 - EAD Mitochondrial Study, Experiment 2 Table 9 - EAD Mitochondrial Study, Experiment 3 Table 10 - LAD Mitochondrial Study, Protein Summary Table 11 - LAD Mitochondrial Study, Experiment 1 Table 12 - LAD Mitochondrial Study, Experiment 2 Table 13 - LAD Mitochondrial Study, Experiment 3 Supplemental Table 1. 112 unique, non-redundant proteins identified and quantified in at least two of the three analytical replicates for all three disease stages. Description Data MCI EAD LAD AATM_HUMAN (P00505) Aspartate aminotransferase, mitochondrial precursor (EC Mean 1.43 1.70 1.31 2.6.1.1) (Transaminase A) (Glutamate oxaloacetate transaminase 2) [MASS=47475] SEM 0.07 0.09 0.09 Count 3.00 3.00 3.00 ACON_HUMAN (Q99798) Aconitate hydratase, mitochondrial precursor (EC 4.2.1.3) Mean 1.24 1.61 1.19 (Citrate hydro-lyase) (Aconitase) [MASS=85425] SEM 0.05 0.17 0.18 Count 3.00 2.00 3.00 ACPM_HUMAN (O14561) Acyl carrier protein, mitochondrial
    [Show full text]
  • Data Sheet Cathepsin V Inhibitor Screening Assay Kit Catalog #79589 Size: 96 Reactions
    6405 Mira Mesa Blvd Ste. 100 San Diego, CA 92121 Tel: 1.858.202.1401 Fax: 1.858.481.8694 Email: [email protected] Data Sheet Cathepsin V Inhibitor Screening Assay Kit Catalog #79589 Size: 96 reactions BACKGROUND: Cathepsin V, also called Cathepsin L2, is a lysosomal cysteine endopeptidase with high sequence homology to cathepsin L and other members of the papain superfamily of cysteine proteinases. Its expression is regulated in a tissue-specific manner and is high in thymus, testis and cornea. Expression analysis of cathepsin V in human tumors revealed widespread expression in colorectal and breast carcinomas, suggesting a possible role in tumor processes. DESCRIPTION: The Cathepsin V Inhibitor Screening Assay Kit is designed to measure the protease activity of Cathepsin V for screening and profiling applications. The Cathepsin V assay kit comes in a convenient 96-well format, with purified Cathepsin V, its fluorogenic substrate, and Cathepsin buffer for 100 enzyme reactions. In addition, the kit includes the cathepsin inhibitor E- 64 for use as a control inhibitor. COMPONENTS: Catalog # Component Amount Storage 80009 Cathepsin V 10 µg -80 °C Fluorogenic Cathepsin Avoid 80349 Substrate 1 (5 mM) 10 µl -20 °C multiple *4X Cathepsin buffer 2 ml -20 °C freeze/thaw E-64 (1 mM) 10 µl -20 °C cycles! 96-well black microplate * Add 120 µl of 0.5 M DTT before use. MATERIALS OR INSTRUMENTS REQUIRED BUT NOT SUPPLIED: 0.5 M DTT in aqueous solution Adjustable micropipettor and sterile tips Fluorescent microplate reader APPLICATIONS: Great for studying enzyme kinetics and screening small molecular inhibitors for drug discovery and HTS applications.
    [Show full text]
  • Felipe Jun Fuzita Molecular Physiology of Digestion In
    FELIPE JUN FUZITA MOLECULAR PHYSIOLOGY OF DIGESTION IN ARACHNIDA: FUNCTIONAL AND COMPARATIVE-EVOLUTIONARY APPROACHES Thesis presented to the Programa de Pós-Graduação Interunidades em Biotecnologia USP/Instituto Butantan/IPT, to obtain the Title of Doctor in Biotechnology. São Paulo 2014 FELIPE JUN FUZITA MOLECULAR PHYSIOLOGY OF DIGESTION IN ARACHNIDA: FUNCTIONAL AND COMPARATIVE-EVOLUTIONARY APPROACHES Thesis presented to the Programa de Pós-Graduação Interunidades em Biotecnologia USP/Instituto Butantan/IPT, to obtain the Title of Doctor in Biotechnology. Concentration area: Biotechnology Advisor: Dr. Adriana Rios Lopes Rocha Corrected version. The original electronic version is available either in the library of the Institute of Biomedical Sciences and in the Digital Library of Theses and Dissertations of the University of Sao Paulo (BDTD). São Paulo 2014 DADOS DE CATALOGAÇÃO NA PUBLICAÇÃO (CIP) Serviço de Biblioteca e Informação Biomédica do Instituto de Ciências Biomédicas da Universidade de São Paulo © reprodução total Fuzita, Felipe Jun. Molecular physiology of digestion in Arachnida: functional and comparative-evolutionary approaches / Felipe Jun Fuzita. -- São Paulo, 2014. Orientador: Profa. Dra. Adriana Rios Lopes Rocha. Tese (Doutorado) – Universidade de São Paulo. Instituto de Ciências Biomédicas. Programa de Pós-Graduação Interunidades em Biotecnologia USP/IPT/Instituto Butantan. Área de concentração: Biotecnologia. Linha de pesquisa: Bioquímica, biologia molecular, espectrometria de massa. Versão do título para o português: Fisiologia molecular da digestão em Arachnida: abordagens funcional e comparativo-evolutiva. 1. Digestão 2. Aranha 3. Escorpião 4. Enzimologia 5. Proteoma 6. Transcriptoma I. Rocha, Profa. Dra. Adriana Rios Lopes I. Universidade de São Paulo. Instituto de Ciências Biomédicas. Programa de Pós-Graduação Interunidades em Biotecnologia USP/IPT/Instituto Butantan III.
    [Show full text]
  • Crystal Structure of Cathepsin X: a Flip–Flop of the Ring of His23
    st8308.qxd 03/22/2000 11:36 Page 305 Research Article 305 Crystal structure of cathepsin X: a flip–flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease Gregor Guncar1, Ivica Klemencic1, Boris Turk1, Vito Turk1, Adriana Karaoglanovic-Carmona2, Luiz Juliano2 and Dušan Turk1* Background: Cathepsin X is a widespread, abundantly expressed papain-like Addresses: 1Department of Biochemistry and v mammalian lysosomal cysteine protease. It exhibits carboxy-monopeptidase as Molecular Biology, Jozef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia and 2Departamento de well as carboxy-dipeptidase activity and shares a similar activity profile with Biofisica, Escola Paulista de Medicina, Rua Tres de cathepsin B. The latter has been implicated in normal physiological events as Maio 100, 04044-020 Sao Paulo, Brazil. well as in various pathological states such as rheumatoid arthritis, Alzheimer’s disease and cancer progression. Thus the question is raised as to which of the *Corresponding author. E-mail: [email protected] two enzyme activities has actually been monitored. Key words: Alzheimer’s disease, carboxypeptidase, Results: The crystal structure of human cathepsin X has been determined at cathepsin B, cathepsin X, papain-like cysteine 2.67 Å resolution. The structure shares the common features of a papain-like protease enzyme fold, but with a unique active site. The most pronounced feature of the Received: 1 November 1999 cathepsin X structure is the mini-loop that includes a short three-residue Revisions requested: 8 December 1999 insertion protruding into the active site of the protease. The residue Tyr27 on Revisions received: 6 January 2000 one side of the loop forms the surface of the S1 substrate-binding site, and Accepted: 7 January 2000 His23 on the other side modulates both carboxy-monopeptidase as well as Published: 29 February 2000 carboxy-dipeptidase activity of the enzyme by binding the C-terminal carboxyl group of a substrate in two different sidechain conformations.
    [Show full text]
  • Deficiency for the Cysteine Protease Cathepsin L Promotes Tumor
    Oncogene (2010) 29, 1611–1621 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 $32.00 www.nature.com/onc ORIGINAL ARTICLE Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis J Dennema¨rker1,6, T Lohmu¨ller1,6, J Mayerle2, M Tacke1, MM Lerch2, LM Coussens3,4, C Peters1,5 and T Reinheckel1,5 1Institute for Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany; 2Department of Gastroenterology, Endocrinology and Nutrition, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany; 3Department of Pathology, University of California, San Francisco, CA, USA; 4Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA and 5Ludwig Heilmeyer Comprehensive Cancer Center and Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Freiburg, Germany To define a functional role for the endosomal/lysosomal Introduction cysteine protease cathepsin L (Ctsl) during squamous carcinogenesis, we generated mice harboring a constitutive Proteases have traditionally been thought to promote Ctsl deficiency in addition to epithelial expression of the invasive growth of carcinomas, contributing to the the human papillomavirus type 16 oncogenes (human spread and homing of metastasizing cancer cells (Dano cytokeratin 14 (K14)–HPV16). We found enhanced tumor et al., 1999). Proteases that function outside tumor cells progression and metastasis in the absence of Ctsl. As have been implicated in these processes because of their tumor progression in K14–HPV16 mice is dependent well-established release from tumors, causing the break- on inflammation and angiogenesis, we examined immune down of basement membranes and extracellular matrix. cell infiltration and vascularization without finding any Thus, extracellular proteases may in part facilitate effect of the Ctsl genotype.
    [Show full text]
  • Human Cathepsin V / Cathepsin L2 / Preproprotein Protein (His Tag)
    Human Cathepsin V / Cathepsin L2 / Preproprotein Protein (His Tag) Catalog Number: 10093-H08H General Information SDS-PAGE: Gene Name Synonym: CATL2; CTSL2; CTSU; CTSV; MGC125957 Protein Construction: A DNA sequence encoding the full length of human cathepsin L2 (NP_001324.2) (Met 1-Val 334) was expressed, with a C-terminal polyhistidine tag. Source: Human Expression Host: HEK293 Cells QC Testing Purity: > 95 % as determined by SDS-PAGE Bio Activity： Protein Description Measured by its ability to cleave the fluorogenic peptide substrate Z-LR- Cathepsin V (CTSV), also known as Cathepsin L2, CTSL2, and CATL2, is AMC, (R&D Systems, Catalog # ES008) . The specific activity is >1000 a member of the peptidase C1 family. It is predominantly expressed in the pmoles/min/μg. thymus and testis. Cathepsin V is also expressed in corneal epithelium, and to a lesser extent in conjuctival epithelium and skin. It is a lysosomal Endotoxin: cysteine proteinase that may play an important role in corneal physiology. It has about 75% protein sequence identity to murine cathepsin L. The fold < 1.0 EU per μg of the protein as determined by the LAL method of this enzyme is similar to the fold adopted by other members of the papain superfamily of cysteine proteases. Cathepsin V has been recently Stability: described as highly homologous to Cathepsin L and exclusively expressed Samples are stable for up to twelve months from date of receipt at -70 ℃ in human thymus and testis. Cathepsin V is the dominant cysteine protease in cortical human thymic epithelial cells, while Cathepsin L and Predicted N terminal: Val 18 Cathepsin S seem to be restricted to dendritic and macrophage-like cells.
    [Show full text]
  • Characterization of the Cathepsin-Like Cysteine Proteinases of Schistosoma Mansoni JOHN P
    INFECTION AND IMMUNITY, Apr. 1996, p. 1328–1334 Vol. 64, No. 4 0019-9567/96/$04.0010 Copyright q 1996, American Society for Microbiology Characterization of the Cathepsin-Like Cysteine Proteinases of Schistosoma mansoni JOHN P. DALTON,1,2 KAREN A. CLOUGH,1 MALCOLM K. JONES,3 1 AND PAUL J. BRINDLEY * Molecular Parasitology Unit, Queensland Institute of Medical Research, and Australian Centre for International & Tropical Health & Nutrition, Post Office, Royal Brisbane Hospital, Queensland 4029,1 and Centre for Microscopy and Microanalysis, University of Queensland, St. Lucia, Queensland 4072,3 Australia, and School of Biological Sciences, Dublin City University, Dublin 9, Republic of Ireland2 Downloaded from Received 5 September 1995/Returned for modification 29 November 1995/Accepted 15 January 1996 Adult Schistosoma mansoni parasites synthesize and secrete both cathepsin L and cathepsin B cysteine proteinases. These cysteine proteinase activities, believed to be involved in hemoglobin digestion by adult schistosomes, were characterized by using specific fluorogenic peptide substrates and zymography. Both cathepsin L- and B-like activities with pH optima of 5.2 and 6.2, respectively, predominated in soluble extracts of worms, and both these activities were secreted by adult worms into the culture medium. The specific activity of cathepsin L was about double that of cathepsin B when each was assayed at its pH optimum, and moreover, the specific activities of cathepsins L and B in extracts of female schistosomes were 50 to 100% higher than in http://iai.asm.org/ extracts of male schistosomes. Analysis of the primary structure of two cloned S. mansoni cathepsins L, here termed cathepsin L1 and cathepsin L2, revealed that they are only 44% similar and that cathepsin L2 showed more identity (52%) with human cathepsin L than with schistosome cathepsin L1.
    [Show full text]
  • Post Mortem Proteolytic Degradation of Myosin Heavy Chain in Skeletal Muscle of Atlantic Cod
    Faculty of Biosciences, Fisheries and Economics Norwegian College of Fishery Science Post mortem proteolytic degradation of myosin heavy chain in skeletal muscle of Atlantic cod Pål Anders Wang A dissertation for the degree of Philosophiae Doctor Spring 2011 Post mortem proteolytic degradation of myosin heavy chain in skeletal muscle of Atlantic cod. Pål Anders Wang A dissertation for the degree of philosophiae doctor University of Tromsø Faculty of Biosciences, Fisheries and Economics Norwegian college of Fishery Science Spring 2011 Contents 1 Acknowledgements.......................................................................................................... II 2 List of publications........................................................................................................ III 3 Sammendrag...................................................................................................................IV 4 Abstract............................................................................................................................ V 5 Introduction ...................................................................................................................... 1 5.1 Fish muscle structure and composition.................................................................. 1 5.1.1 General structure and composition ................................................................ 1 5.1.2 Myosin ............................................................................................................... 3 5.2 Post
    [Show full text]
  • Death Penalty for Keratinocytes: Apoptosis Versus Cornification
    Cell Death and Differentiation (2005) 12, 1497–1508 & 2005 Nature Publishing Group All rights reserved 1350-9047/05 $30.00 www.nature.com/cdd Review Death penalty for keratinocytes: apoptosis versus cornification S Lippens1,2, G Denecker1, P Ovaere1, P Vandenabeele*,1 and apoptosis, necrosis or autophagy ultimately result in the W Declercq*,1 elimination of particular cells from a tissue. However, in specialized forms of differentiation, dead cell corpses are not 1 Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical removed but maintained to fulfil a specific function. These Research, VIB (Flanders Interuniversity Institute for Biotechnology) and Ghent developmental cell death programs result in the production of University, Technologiepark 927, B-9052 Zwijnaarde, Belgium 2 differentiated ‘storage’ cells containing large amounts of Current address: Institute de Biochimie, Universite´ de Lausanne, Chemin des specific proteins or other substances. Examples of such Boveresses 155, CH-1066 Epalinges, Switzerland * Corresponding authors: W Declercq and P Vandenabeele, Molecular Signaling differentiation programs occur in the stalk of the slime mold and Cell Death Unit, Department of Molecular Biomedical Research, Dictyostelium, during xylogenesis in plants, erythrocyte Technologiepark 927, B-9052 Zwijnaarde, Belgium. differentiation, lens fiber formation and cornification of Tel: þ 32 9 33137 60 Fax: þ 32 9 3313609; keratinocytes in the skin. E-mails: [email protected], Both apoptosis and keratinocyte cornification share some [email protected] similarities at the cellular and molecular level, such as loss of an intact nucleus and other organelles, cytoskeleton and cell Received 17.6.04; revised 23.3.05; accepted 07.4.05 Edited by G Melino shape changes, involvement of proteolytic events and mitochondrial changes.
    [Show full text]
  • CTSL2 Is a Pro-Apoptotic Target of E2F1 and a Modulator of Histone Deacetylase Inhibitor and DNA Damage-Induced Apoptosis
    Oncogene (2014) 33, 1249–1257 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc ORIGINAL ARTICLE CTSL2 is a pro-apoptotic target of E2F1 and a modulator of histone deacetylase inhibitor and DNA damage-induced apoptosis CH Wong1,5,ZWu2,5 and Q Yu1,3,4 Aberrant regulation of the pRB/E2F1 pathway has been invariably linked to inappropriate proliferation and/apoptosis in human cancers. Therefore, understanding the intricacies of the signaling pathway and identification of novel E2F1 targets involved in apoptosis could pave way for new therapeutic manipulation. Here, we identified CTSL2 (cathepsin L2/cathepsin V) as a novel E2F1 target that participates in E2F1-dependent apoptosis. We showed that E2F1 directly binds to CTSL2 promoter and that CTSL2 is regulated by both exogenous and endogenous E2F1. RNAi-mediated depletion of CTSL2 effectively abrogated ectopic E2F1-induced apoptosis, coupled with reduced lysosomal membrane permeabilization (LMP) and mitochondrial membrane depolarization. CTSL2 knockdown also inhibited apoptosis mediated by the endogenous E2F1 activated by DNA damage. Furthermore, we showed that CTSL2 depletion in cancer cells resulted in inhibition of histone deacetylase inhibitor (HDACi)- induced apoptosis, and conversely ectopic overexpression of CTSL2-sensitized cancer cells to HDACi. This study uncovered a novel E2F1 target implicated in LMP and apoptosis activation, as well as in the modulation of HDACi and chemotherapeutic drugs response. Oncogene (2014) 33, 1249–1257; doi:10.1038/onc.2013.72; published online 1 April 2013 Keywords: E2F1; apoptosis; CTSL2 INTRODUCTION Here, through a large-scale gene expression analysis using an E2F transcription factor family members have diverse roles in cellular E2F1-confined system, we identified CTSL2 gene, encoding physiology and homeostasis.1,2 Among them, E2F1 (and perhaps cathepsin like 2 (cathepsin L2/cathepsin V), as a novel E2F3) possesses a unique ability to induce apoptosis,3 which has E2F1 target.
    [Show full text]
  • Cathepsin L2, a Novel Human Cysteine Proteinase Produced by Breast and Colorectal Carcinomas1
    [CANCERRESEARCH58,1624-1630, April 15. 19981 Advances in Brief Cathepsin L2, a Novel Human Cysteine Proteinase Produced by Breast and Colorectal Carcinomas1 Ifligo Santamarla, Gloria Velasco, Maite Cazorla, Antonio Fueyo, Elias Campo, and Carlos López-Otmn2 Departamento de Bioquimica y Biolog(a Molecular (I .S., G. V., C. L-O.J and Biolog(a Funcional (A F], Facultad de Medicina. Universidad de Oviedo, 33006 Oviedo. and Departamento de Anatom(a Patoldgica, Hospital Clmnico—Barcelona,08036Barcelona, [M. C., E. C.!, Spain Abstract (3); (b) cathepsin L (4); (c) cathepsin H (5); (d) cathepsin S (6); (e) cathepsin C (7); (/) cathepsin 0 (8); (g) cathepsin K (9); and (h) We have identified and cloned a new member of the papain family of cathepsin W (10). Furthermore, several groups have described the cysteine proteinases from a human brain eDNA library. The isolated existence of additional cysteine proteinases including cathepsins M, cDNA codes for a polypeptide of 334 amino acids that exhibits all of the structural features characteristic of cysteine proteinases, including the N, P. and T, which were originally identified because of their degrad active site cysteine residue essential for peptide hydrolysis. PairWise corn ing activity on specific substrates such as aldolase, collagen, prom parisons of this amino acid sequence with the remaining human cysteine sulin, or tyrosine aminotransferase, but whose characterization at the proteinases identified to date showed a high percentage of identity (78%) molecular level has not yet been reported (11—14). with cathepsin L; the percentage of identity with all other members of the Structural comparisons between the different members of the cys family was much lower (<40%).
    [Show full text]
  • A Genomic Analysis of Rat Proteases and Protease Inhibitors
    A genomic analysis of rat proteases and protease inhibitors Xose S. Puente and Carlos López-Otín Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, 33006-Oviedo, Spain Send correspondence to: Carlos López-Otín Departamento de Bioquímica y Biología Molecular Facultad de Medicina, Universidad de Oviedo 33006 Oviedo-SPAIN Tel. 34-985-104201; Fax: 34-985-103564 E-mail: [email protected] Proteases perform fundamental roles in multiple biological processes and are associated with a growing number of pathological conditions that involve abnormal or deficient functions of these enzymes. The availability of the rat genome sequence has opened the possibility to perform a global analysis of the complete protease repertoire or degradome of this model organism. The rat degradome consists of at least 626 proteases and homologs, which are distributed into five catalytic classes: 24 aspartic, 160 cysteine, 192 metallo, 221 serine, and 29 threonine proteases. Overall, this distribution is similar to that of the mouse degradome, but significatively more complex than that corresponding to the human degradome composed of 561 proteases and homologs. This increased complexity of the rat protease complement mainly derives from the expansion of several gene families including placental cathepsins, testases, kallikreins and hematopoietic serine proteases, involved in reproductive or immunological functions. These protease families have also evolved differently in the rat and mouse genomes and may contribute to explain some functional differences between these two closely related species. Likewise, genomic analysis of rat protease inhibitors has shown some differences with the mouse protease inhibitor complement and the marked expansion of families of cysteine and serine protease inhibitors in rat and mouse with respect to human.
    [Show full text]